- Aegis starts Evoke Pharma (EVOK) at Buy with a $60 target (that represents upside of ~636%).
- Analyst Raghuram Selvaraju likes the regulatory chances for EVK-001 (intranasal metoclopramide).
- "Since the compound in question is already approved for the same indication in which Evoke is aiming to test it, this program seems a low-risk proposition," Selvaraju says.
- Shares +54% premarket
Aegis looks for Evoke Pharma to increase sevenfold
Nov 19 2013, 09:14 ET